James Investment Research Inc. Has $5.63 Million Holdings in Johnson & Johnson $JNJ

James Investment Research Inc. cut its holdings in Johnson & Johnson (NYSE:JNJ) by 3.4% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 36,834 shares of the company’s stock after selling 1,287 shares during the period. James Investment Research Inc.’s holdings in Johnson & Johnson were worth $5,626,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of JNJ. Nuveen LLC acquired a new position in shares of Johnson & Johnson in the first quarter valued at about $1,369,188,000. Bank of New York Mellon Corp grew its stake in Johnson & Johnson by 26.4% during the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock worth $3,844,580,000 after buying an additional 4,842,582 shares in the last quarter. Pacer Advisors Inc. grew its stake in Johnson & Johnson by 1,382.0% during the first quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company’s stock worth $502,509,000 after buying an additional 2,825,626 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in Johnson & Johnson by 159.6% during the second quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock worth $635,327,000 after buying an additional 2,557,388 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC acquired a new stake in Johnson & Johnson during the second quarter worth about $401,420,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have issued reports on JNJ. Daiwa Capital Markets upgraded shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective on the stock in a research note on Monday, October 20th. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Daiwa America upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. JPMorgan Chase & Co. increased their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 16th. Finally, Stifel Nicolaus increased their price objective on shares of Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a research note on Wednesday, October 15th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $199.05.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Down 1.8%

JNJ stock opened at $186.94 on Wednesday. The stock has a market capitalization of $450.40 billion, a P/E ratio of 18.04, a price-to-earnings-growth ratio of 2.24 and a beta of 0.40. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $194.48. The firm has a 50-day moving average price of $182.72 and a 200-day moving average price of $166.92.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.